Appealing Denied Mental Health and Substance Use Insurance Claims

Denied mental health and substance use disorder (SUD) insurance claims represent one of the most contested areas of health coverage disputes in the United States. Federal parity law, state mandates, and ACA protections create a layered framework of appeal rights that policyholders can invoke — but navigating that framework requires understanding which rules apply to a specific plan type. This page covers the regulatory basis for mental health and SUD appeal rights, the mechanics of filing internal and external appeals, the most common denial scenarios, and the decision thresholds that determine when an appeal is likely to succeed.

Definition and scope

Mental health and substance use disorder insurance appeals are formal challenges to a plan's refusal to cover behavioral health services — including psychiatric inpatient care, outpatient therapy, medication-assisted treatment (MAT), residential rehabilitation, and crisis stabilization. The primary federal statute governing these disputes is the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), which prohibits group health plans and insurers from imposing treatment limitations on mental health and SUD benefits that are more restrictive than those applied to comparable medical or surgical benefits (U.S. Department of Labor, MHPAEA Overview).

Scope varies by plan type:

Employer-sponsored plans governed by ERISA fall under MHPAEA and DOL enforcement jurisdiction.
Individual and small-group marketplace plans are subject to both MHPAEA and ACA Section 1311 essential health benefit (EHB) requirements, which classify mental health and SUD care as mandatory EHBs (HealthCare.gov, Essential Health Benefits).
Medicare Advantage plans must comply with MHPAEA under CMS rules.
Medicaid managed care plans are covered by MHPAEA as extended by the 21st Century Cures Act (2016).
Short-term limited-duration plans are explicitly excluded from MHPAEA protections.

The insurance-appeals-for-denied-mental-health-claims resource provides a parallel treatment of claim-level denial mechanics specific to behavioral health billing codes.

How it works

Appeals for denied mental health and SUD claims follow a structured sequence. The insurance-appeals-process-overview page outlines the general framework; the steps specific to behavioral health denials are as follows:

Obtain the denial explanation. Plans are required under ACA regulations (45 CFR §147.136) to provide a written Explanation of Benefits (EOB) specifying the denial reason, the clinical criteria applied, and the plan provision cited.
Identify the denial category. Denials fall into three primary types: (a) medical necessity, where the plan claims the treatment is not clinically required; (b) level-of-care, where a higher-intensity setting (e.g., inpatient) is denied in favor of a lower one; or (c) parity violation, where the plan imposes non-quantitative treatment limitations (NQTLs) on behavioral health that have no equivalent on medical/surgical benefits.
File an internal appeal. Under ACA rules, plans must allow at least one level of internal appeal. The standard deadline for filing is 180 days from receipt of the denial notice (45 CFR §147.136). The plan must issue a decision within 60 days for non-urgent claims.
Request the comparative analysis. Under the Consolidated Appropriations Act, 2022 (CAA 2022), effective March 15, 2022, plans must provide, upon request, a written analysis demonstrating that NQTLs applied to mental health and SUD benefits are no more restrictive than those applied to medical/surgical benefits. CAA 2022 strengthened and clarified enforcement of these comparative analysis requirements, building on the framework established by CAA 2021, and plans are now required to perform and document this analysis proactively rather than only upon regulatory request. This document is critical evidence in parity-based appeals.
Proceed to external review. If the internal appeal is denied, policyholders have the right to request external review through an Independent Review Organization (IRO) for medical necessity and parity disputes. Federal external review standards under ERISA and the ACA require a decision within 45 days for standard reviews and 72 hours for expedited reviews.
Escalate to regulatory bodies. Unresolved parity complaints can be filed with the DOL (for ERISA plans), HHS Office of Civil Rights, or a state insurance commissioner.

Common scenarios

Inpatient psychiatric admission denial. The plan approves an emergency psychiatric admission but denies continued inpatient stay after 3–5 days, citing its internal clinical criteria that the patient is "no longer a danger to self or others." A parity appeal challenges whether the plan applies an equivalent "improvement standard" to comparable medical/surgical inpatient stays — a standard the Centers for Medicare & Medicaid Services (CMS) has specifically addressed in parity enforcement guidance.

Residential rehabilitation denial. Plans frequently deny residential SUD treatment on medical necessity grounds, arguing outpatient services are sufficient. The ASAM Criteria (American Society of Addiction Medicine Patient Placement Criteria) is the most widely cited clinical standard for level-of-care determinations; appeals citing ASAM documentation that outpatient treatment is contraindicated carry significant weight in IRO reviews.

Prior authorization for MAT. Step therapy or fail-first requirements that demand a patient attempt and fail one medication before approving another (e.g., requiring buprenorphine trial before approving naltrexone) may constitute an NQTL parity violation if no equivalent step-therapy protocol applies to medical treatments. For procedural background on prior authorization disputes, see prior-authorization-denials-and-appeals.

Outpatient therapy visit limits. A plan caps outpatient mental health visits at 30 per year while imposing no comparable annual visit cap on outpatient physical therapy. This is a textbook quantitative treatment limitation (QTL) parity violation under MHPAEA §2726(a)(3)(B).

Substance use detox denial. Denial of medically supervised detoxification, particularly opioid or alcohol detox, is one of the highest-risk denial categories. These denials frequently fail IRO review when supported by treating-physician documentation citing withdrawal risk severity.

Decision boundaries

The outcome of a mental health or SUD insurance appeal turns on three primary analytical thresholds:

Parity compliance vs. non-compliance. Under MHPAEA, the comparison is always between a behavioral health benefit and its "substantially similar" medical/surgical counterpart within the same classification (inpatient in-network, outpatient in-network, etc.). A denial that applies criteria with no medical/surgical parallel is facially vulnerable. The federal-insurance-appeal-rights page details the DOL enforcement process for parity violations.

Medical necessity standard applied. Plans are permitted to make medical necessity determinations, but the criteria used must be disclosed and must not be more stringent for behavioral health than for analogous medical conditions. When a plan uses proprietary criteria that diverge from the ASAM Criteria or American Psychiatric Association (APA) guidelines without justification, IROs frequently side with the claimant.

Plan type determines the applicable appeal path. ERISA-governed employer plans and ACA marketplace plans follow different procedural tracks. ERISA plans ultimately allow federal court review under 29 U.S.C. §1132 after exhaustion of internal remedies. ACA marketplace plan appeals may proceed through marketplace-plan-appeals-healthcare-gov. Medicaid enrollees use a separate administrative hearing process under 42 CFR Part 431. Selecting the wrong appeals track — for example, filing a state insurance department complaint for an ERISA self-funded plan, which is exempt from state insurance regulation — can forfeit time-sensitive rights. The erisa-appeals-employer-sponsored-plans page addresses ERISA-specific procedural requirements in detail.

Strength of clinical documentation. IRO reviewers assess whether treating clinicians documented the clinical necessity of the denied level of care using recognized criteria. Appeals supported by a psychiatrist or addiction medicine specialist letter citing ASAM or DSM-5 criteria directly, and specifically rebutting the plan's denial rationale, resolve in the claimant's favor at materially higher rates than appeals relying solely on billing records (URAC External Review Accreditation Standards, 2022).

References

📜 5 regulatory citations referenced · ✅ Citations verified Feb 25, 2026 · View update log

Explore This Site

Regulations & Safety Regulatory References Tools & Calculators Compound Interest Calculator